Bioequivalence Study of Saxagliptin and Glucophage Combination Formulations in Healthy Subjects (B)
- Conditions
- Type 2 Diabetes Mellitus
- Interventions
- Registration Number
- NCT00897390
- Lead Sponsor
- AstraZeneca
- Brief Summary
To demonstrate bioequivalence of a 2.5 mg saxagliptin/1000 mg metformin (glucophage) immediate release (IR) fixed dose combination (FDC) tablet to the 2.5 mg saxagliptin tablet and 1000 mg metformin IR tablet co-administered to healthy subjects in a fasted and in a fed state.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 24
- Men and women ages 19 to 45 inclusive
- Healthy subjects as determined by no clinically significant deviation from normal in medical history, physical examination, electrocardiograms (ECGs), and clinical laboratory determinations
- Body Mass Index (BMI) of 18 to 32 kg/m2, inclusive. BMI = weight (kg)/ [height (m)]2
- Women of child-bearing potential (WOCBP) who are unwilling or unable to use acceptable barrier methods (condoms and spermicides) to avoid pregnancy for the entire study period and for up to 8 weeks after the last dose of investigational product
- Any significant acute or chronic medical illness
- Current or recent (within 3 months) gastrointestinal disease
- Any major surgery within 4 weeks of study drug administration
- History of allergy to Dipeptidyl peptidase 4 (DPP4) inhibitor or related compounds
- History of allergy or intolerance to metformin or other similar acting agents
- Prior exposure to saxagliptin
- Prior exposure to metformin within 3 months of study drug administration
- Estimated creatinine clearance (Clcr) of < 80ml/min using the Cockcroft Gault formula
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- CROSSOVER
- Arm && Interventions
Group Intervention Description Arm A Saxagliptin Co-administration of single oral doses of a 2.5 mg tablet of saxagliptin and a 1000 mg tablet of metformin IR under fasted conditions Arm A Metformin IR (glucophage) Co-administration of single oral doses of a 2.5 mg tablet of saxagliptin and a 1000 mg tablet of metformin IR under fasted conditions Arm B Saxagliptin + Metformin IR (FDC) Single oral dose of a FDC tablet consisting of 2.5 mg saxagliptin/ 1000 mg metformin IR under fasted conditions Arm C Saxagliptin Co-administration of single oral doses of a 2.5 mg tablet of saxagliptin and a 1000 mg tablet of metformin IR under fed conditions with a standard meal Arm C Metformin IR (glucophage) Co-administration of single oral doses of a 2.5 mg tablet of saxagliptin and a 1000 mg tablet of metformin IR under fed conditions with a standard meal Arm D Saxagliptin + Metformin IR (FDC) Single oral dose of a FDC tablet consisting of 2.5 mg saxagliptin/ 1000 mg metformin IR under fed conditions with a standard meal
- Primary Outcome Measures
Name Time Method Saxagliptin PK Parameter Plasma Terminal Half-life (T-HALF) pre-dose, post-dose at 15, 30, 45, 90 minutes, hours 1, 2, 3, 4, 6, 8, 12, 18, 24, 36 and 48 of each period Single-dose PK parameters of saxagliptin were derived from plasma concentration versus time data.
Saxagliptin Pharmacokinetic (PK) Parameter Area Under the Plasma Concentration-Time Curve From Time Zero Extrapolated to Infinite Time (AUC[INF]) pre-dose, post-dose at 15, 30, 45, 90 minutes, hours 1, 2, 3, 4, 6, 8, 12, 18, 24, 36 and 48 of each period Single-dose PK parameters of saxagliptin were derived from plasma concentration versus time data.
Saxagliptin PK Parameter Area Under the Plasma Concentration-time Curve From Time Zero to the Time of the Last Quantifiable Plasma Concentration (AUC[0-T]) pre-dose, post-dose at 15, 30, 45, 90 minutes, hours 1, 2, 3, 4, 6, 8, 12, 18, 24, 36 and 48 of each period Single-dose PK parameters of saxagliptin were derived from plasma concentration versus time data.
Saxagliptin PK Parameter Maximum Observed Plasma Concentration (Cmax) pre-dose, post-dose at 15, 30, 45, 90 minutes, hours 1, 2, 3, 4, 6, 8, 12, 18, 24, 36 and 48 of each period Single-dose PK parameters of saxagliptin were derived from plasma concentration versus time data.
Metformin PK Parameter Cmax pre-dose, post-dose at 15, 30, 45, 90 minutes, hours 1, 2, 3, 4, 6, 8, 12, 18, 24, 36 and 48 of each period Single-dose PK parameters of metformin were derived from plasma concentration versus time data.
Metformin PK Parameter T-HALF pre-dose, post-dose at 15, 30, 45, 90 minutes, hours 1, 2, 3, 4, 6, 8, 12, 18, 24, 36 and 48 of each period Single-dose PK parameters of metformin were derived from plasma concentration versus time data.
Metformin PK Parameter Tmax pre-dose, post-dose at 15, 30, 45, 90 minutes, hours 1, 2, 3, 4, 6, 8, 12, 18, 24, 36 and 48 of each period Single-dose PK parameters of metformin were derived from plasma concentration versus time data.
Saxagliptin PK Parameter Time of Maximum Observed Plasma Concentration (Tmax) pre-dose, post-dose at 15, 30, 45, 90 minutes, hours 1, 2, 3, 4, 6, 8, 12, 18, 24, 36 and 48 of each period Single-dose PK parameters of saxagliptin were derived from plasma concentration versus time data.
Metformin PK Parameter AUC(INF) pre-dose, post-dose at 15, 30, 45, 90 minutes, hours 1, 2, 3, 4, 6, 8, 12, 18, 24, 36 and 48 of each period Single-dose PK parameters of metformin were derived from plasma concentration versus time data.
Metformin PK Parameter AUC(0-T) pre-dose, post-dose at 15, 30, 45, 90 minutes, hours 1, 2, 3, 4, 6, 8, 12, 18, 24, 36 and 48 of each period Single-dose PK parameters of metformin were derived from plasma concentration versus time data.
- Secondary Outcome Measures
Name Time Method BMS-510849 PK Parameter AUC(INF) pre-dose, post-dose at 15, 30, 45, 90 minutes, hours 1, 2, 3, 4, 6, 8, 12, 18, 24, 36 and 48 of each period Single-dose PK parameters of the active metabolite of saxagliptin, BMS-510849, were derived from plasma concentration versus time data.
BMS-510849 PK Parameter AUC(0-T) pre-dose, post-dose at 15, 30, 45, 90 minutes, hours 1, 2, 3, 4, 6, 8, 12, 18, 24, 36 and 48 of each period Single-dose PK parameters of the active metabolite of saxagliptin, BMS-510849, were derived from plasma concentration versus time data.
BMS-510849 PK Parameter Cmax pre-dose, post-dose at 15, 30, 45, 90 minutes, hours 1, 2, 3, 4, 6, 8, 12, 18, 24, 36 and 48 of each period Single-dose PK parameters of the active metabolite of saxagliptin, BMS-510849, were derived from plasma concentration versus time data.
BMS-510849 PK Parameter T-Half pre-dose, post-dose at 15, 30, 45, 90 minutes, hours 1, 2, 3, 4, 6, 8, 12, 18, 24, 36 and 48 of each period Single-dose PK parameters of the active metabolite of saxagliptin, BMS-510849, were derived from their respective plasma concentration versus time data.
Electrocardiogram (ECG), Vital Sign, and Physical Finding Abnormalities At Screening (within 21 days of Study Day 1), Day -1 of Period 1 (ECG and Physical only), Day 1 of Periods 1-4 (Vitals only), at Study Discharge (Day 3 of Period 4) or Discontinuation 12-lead Electrocardiogram (ECG), Vital Sign (body temperature, respiratory rate, seated blood pressure and heart rate), and Physical Finding Abnormalities reported by investigator as AEs.
BMS-510849 PK Parameter T-Max pre-dose, post-dose at 15, 30, 45, 90 minutes, hours 1, 2, 3, 4, 6, 8, 12, 18, 24, 36 and 48 of each period Single-dose PK parameters of the active metabolite of saxagliptin, BMS-510849, were derived from plasma concentration versus time data.
Deaths, Serious Adverse Events (SAEs), Adverse Events (AEs), and Discontinuations Due to AEs AEs collected from Day 1/Period 1 through study discharge (study duration: approximately 45 days). SAEs collected from date of written consent until 30 days post discontinuation of dosing or subject's participation in the study. An AE is defined as any new untoward medical occurrence or worsening of a pre-existing medical condition in a patient or clinical investigation subject administered an investigational (medicinal) product and that does not necessarily have a causal relationship with this treatment. An SAE is any untoward medical occurrence that at any dose results in death, is life-threatening, requires inpatient hospitalization or causes prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, or is an important medical event.
AEs of Special Interest AEs collected from Day 1/Period 1 through study discharge (study duration: approximately 45 days). See Outcome Measure 16 for a definition of AEs. AEs of clinical interest for saxagliptin were defined as those relating to the following:skin disorders, infection-related AEs (system organ class \[SOC\]: Infections and Infestations), thrombocytopenia, lymphopenia, hypoglycemia, cardiovascular AEs indicative of acute cardiovascular events, localized edema, fractures, pancreatitis, and AEs of hypersensitivity.
Number of Participants With Marked Laboratory Abnormalities (MA) Within 21 days of study Day 1, Days 1-3 of Periods 1, 2, 3, and 4. Laboratory abnormalities=any result that is clinically significant, met the definition of an SAE, required discontinuation or interruption of study drug, or required specific corrective therapy. Upper normal (UN)/lower normal (LN) values: leukocytes UN, 11.40x10\^3 c/uL; absolute neutrophils/bands LN, 1.500x10\^3 c/uL; aspartate aminotransferase UN, 48 U/L; alanine aminotransferase UN, 67 U/L; blood urea nitrogen UN, 20.0 mg/dL; creatine kinase UN, 350 U/L; lactate dehydrogenase UN, 249 U/L.
Number of Participants With Marked Urinalysis Abnormalities Within 21 days of study Day 1, Days 1-3 of Periods 1, 2, 3, and 4. Protein, Urine Abnormality: if value \>= 2+ (or if pretreatment value \>= 1+, then \>= 2 \* pretreatment). Glucose, Urine Abnormality: if value \>= 2+ (or if pretreatment value \>= 1+, then \>= 2 \* pretreatment). Blood, Urine Abnormality: if value \>= 2+ (or if pretreatment value \>= 1+, then \>= 2 \* pretreatment). White Blood Cell (WBC), Urine Abnormality: if value \>= 2+ (or if pretreatment value \>= 2+, then \>= 4+). Red Blood Cell (RBC), Urine Abnormality: if value \>= 2+ (or if pretreatment value \>= 2+, then \>= 4+). (The '+' is a normal lab result and refers to the magnitude of the finding.)
Trial Locations
- Locations (1)
Mds Pharma Services
🇺🇸Lincoln, Nebraska, United States